Providence Holy Cross Medical Center is the first Providence hospital in the San Fernando Valley to offer a minimally ...
Dedicated COPD respiratory therapists can improve inhaler use, ensure adherence, and bridge care transitions, explained Megan ...
Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic ...
Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...
New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy.
Ensifentrine significantly improved lung function after 12 weeks in patients with moderate to severe COPD with and without ...
Learn how accelerating drug discovery is reshaping the pathway from lab findings to effective therapies with real-world data.
Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation ...
The respiratory medical community is moving toward shared decision-making in self-managing chronic respiratory disease, but ...
The FDA accepted a new drug application for a single inhaler that contains beclomethasone dipropionate, formoterol fumarate ...
AI health company Pangaea Data today launched its next-generation platform, designed to help clinicians - Read more from ...
As smoking rates continue to fall, the rise of vaping has blurred the lines between helping smokers quit and leading people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback